National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting, 58388-58389 [2024-15787]

Download as PDF khammond on DSKJM1Z7X2PROD with NOTICES 58388 Federal Register / Vol. 89, No. 138 / Thursday, July 18, 2024 / Notices 42. Jenny Schroth and Jeffrey Robert Schroth on behalf of D. S., Appleton, Wisconsin, Court of Federal Claims No: 24–0585V 43. Holly C. Nelson, Stratford, Connecticut, Court of Federal Claims No: 24–0586V 44. Jason Miller, Napoleonville, Louisiana, Court of Federal Claims No: 24–0587V 45. Sheri Blake, Fayetteville, Arkansas, Court of Federal Claims No: 24–0589V 46. Donna Marin, Louisville, Kentucky, Court of Federal Claims No: 24–0591V 47. John Sproul, Ypsilanti, Michigan, Court of Federal Claims No: 24–0599V 48. Karen Mangold, Charlotte, North Carolina, Court of Federal Claims No: 24–0601V 49. Bonnie McClelland, Tyler, Texas, Court of Federal Claims No: 24–0605V 50. Stanka Vujovic, Englewood, New Jersey, Court of Federal Claims No: 24–0607V 51. Patricia Romero, Mountain View, California, Court of Federal Claims No: 24–0608V 52. Nick McGuire, Oxnard, California, Court of Federal Claims No: 24–0609V 53. Sterling Conley, Sarasota, Florida, Court of Federal Claims No: 24–0610V 54. Rene Ahern, Kirkland, Washington, Court of Federal Claims No: 24–0611V 55. Kelly Kennedy, Maryville, Tennessee, Court of Federal Claims No: 24–0615V 56. Kent A. Stensrud, Madison, Minnesota, Court of Federal Claims No: 24–0616V 57. Crystal Green, Kennewick, Washington, Court of Federal Claims No: 24–0621V 58. Aimee Sher on behalf of C. S., St. Louis, Missouri, Court of Federal Claims No: 24–0626V 59. Justine Guillen, Los Angeles, California, Court of Federal Claims No: 24–0627V 60. Brian Weiser, Chicago, Illinois, Court of Federal Claims No: 24–0628V 61. Garrett Keuer, Lubbock, Texas, Court of Federal Claims No: 24–0629V 62. Dennis Geary, Mount Pleasant, Pennsylvania, Court of Federal Claims No: 24–0631V 63. William Mayfield, San Antonio, Texas, Court of Federal Claims No: 24–0632V 64. Nicola Tognara, Phoenix, Arizona, Court of Federal Claims No: 24–0633V 65. Mary A. Walker-Jackson, Philadelphia, Pennsylvania, Court of Federal Claims No: 24–0635V 66. Ronald Shelk, Chicago, Illinois, Court of Federal Claims No: 24–0636V 67. Bahaeldin Hussein, Falls Church, Virginia, Court of Federal Claims No: 24–0638V 68. Jamie Fletcher and Aaron Fletcher on behalf of G. F., Ellsworth, South VerDate Sep<11>2014 16:47 Jul 17, 2024 Jkt 262001 Dakota, Court of Federal Claims No: 24–0640V 69. Karen Maghirang on behalf of M. M., Camden, Missouri, Court of Federal Claims No: 24–0641V 70. Ann Heinrichs, Chicago, Illinois, Court of Federal Claims No: 24–0643V 71. Pamela Kahn, Boston, Massachusetts, Court of Federal Claims No: 24–0644V 72. Nancy Smacchi, Wilkes-Barre, Pennsylvania, Court of Federal Claims No: 24–0649V 73. Mahya Sheikhzadeh, San Jose, California, Court of Federal Claims No: 24–0650V 74. Mary Curry, Missoula, Montana, Court of Federal Claims No: 24–0651V 75. Raleigh Gharbi on behalf of A. G., Navarre, Florida, Court of Federal Claims No: 24–0652V 76. Vergie Tate-Singleton, Flossmoor, Illinois, Court of Federal Claims No: 24–0653V 77. Sheila Flynn, Roseville, Minnesota, Court of Federal Claims No: 24–0658V 78. Karen Ranieri on behalf of I. R., Boston, Massachusetts, Court of Federal Claims No: 24–0659V 79. Gail Mitchell, McDonough, Georgia, Court of Federal Claims No: 24–0660V 80. Benson Kravtin, Brooklyn, New York, Court of Federal Claims No: 24– 0661V 81. Jessica Massie, Marathon, Florida, Court of Federal Claims No: 24–0662V 82. Gary Mahana, Toms River, New Jersey, Court of Federal Claims No: 24–0664V 83. Laura Missiha, Houston, Texas, Court of Federal Claims No: 24–0666V 84. Jacopo Vecchiato, Kirkland, Washington, Court of Federal Claims No: 24–0667V 85. Alicia M. Urbas, Holly Springs, North Carolina, Court of Federal Claims No: 24–0668V 86. Jennifer Mccorkle, Harrisburg, Pennsylvania, Court of Federal Claims No: 24–0669V 87. Mark Lanese on behalf of Christine Lanese, Deceased, Aventura, Florida, Court of Federal Claims No: 24–0674V 88. Mandy Dols, Moose Lake, Minnesota, Court of Federal Claims No: 24–0675V 89. Symentha Chambers, Houston, Texas, Court of Federal Claims No: 24–0677V 90. Loretta Jackson, Chandler, Arizona, Court of Federal Claims No: 24–0678V 91. Brandon Mason, Boscobel, Wisconsin, Court of Federal Claims No: 24–0679V 92. Marta Ubiles, Allentown, Pennsylvania, Court of Federal Claims No: 24–0680V 93. Mark Engle, Chewelah, Washington, Court of Federal Claims No: 24–0681V PO 00000 Frm 00062 Fmt 4703 Sfmt 4703 94. Valerie McClure, Rice Lake, Wisconsin, Court of Federal Claims No: 24–0682V 95. Debra White, Wheat Ridge, Colorado, Court of Federal Claims No: 24–0685V 96. Veta Wholey, Fredericksburg, Virginia, Court of Federal Claims No: 24–0686V 97. Mark Counts, Warren, Michigan, Court of Federal Claims No: 24–0688V 98. Breia Weiland on behalf of B. W., Phoenix, Arizona, Court of Federal Claims No: 24–0689V 99. Julie Boudrie, Monroe, Michigan, Court of Federal Claims No: 24–0690V [FR Doc. 2024–15817 Filed 7–17–24; 8:45 am] BILLING CODE 4165–15–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Resource Related Research Projects (R24 Clinical Trial Not Allowed). Date: August 12, 2024. Time: 10:30 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G11A, Rockville, MD 20892 (Video Assisted Meeting). Contact Person: J. Bruce Sundstrom, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G11A, Rockville, MD 20892, 240–669–5045 sundstromj@ niaid.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, E:\FR\FM\18JYN1.SGM 18JYN1 Federal Register / Vol. 89, No. 138 / Thursday, July 18, 2024 / Notices Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: July 12, 2024. Lauren A. Fleck, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2024–15787 Filed 7–17–24; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Closed Meetings khammond on DSKJM1Z7X2PROD with NOTICES Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review SEP–E. Date: September 11–12, 2024. Time: 9:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Anita T. Tandle, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850, 240–276–5085, tandlea@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; The NCI Transition, Clinical, and Community Oncology Career Development Awards and Institutional Research and Education Training Grants Meeting. Date: September 19, 2024. Time: 9:00 a.m. to 7:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W234, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, VerDate Sep<11>2014 16:47 Jul 17, 2024 Jkt 262001 Room 7W234, Rockville, Maryland 20850, 240–276–6368, Stoicaa2@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review SEP–B. Date: September 19–20, 2024. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W618, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: E. Tian, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W618, Rockville, Maryland 20850, 240–276–6611, tiane@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–3: NCI Clinical and Translational Cancer Research. Date: September 25, 2024. Time: 9:30 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Prashant Sharma, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W612, Rockville, Maryland 20850, 240–275–6351, prashant.sharma@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review SEP–A. Date: September 26–27, 2024. Time: 9:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W120, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Majed M. Hamawy, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive Room 7W120, Rockville, Maryland 20850, 240–276–6457, mh101v@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI Program Project (P01) Review SEP–D. Date: September 26–27, 2024. Time: 9:00 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W244, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Amr M. Ghaleb, Ph.D., Scientific Review Officer, Research Program Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W244, Rockville, Maryland 20850, 240–276–6611, amr.ghaleb@nih.gov. PO 00000 Frm 00063 Fmt 4703 Sfmt 4703 58389 Name of Committee: National Cancer Institute Special Emphasis Panel; SEP–5: NCI Clinical and Translational Cancer Research. Date: September 26, 2024. Time: 9:30 a.m. to 5:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Shree Ram Singh, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Rockville, Maryland 20850, 240–672–6175, singhshr@ mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; NCI SPORE (P50) Review SEP–I. Date: September 26–27, 2024. Time: 9:30 a.m. to 6:30 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W244, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: John Paul Cairns, Ph.D., Scientific Review Officer, Research Programs Review, Branch Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W244, Rockville, Maryland 20850, 240–276–5415, paul.cairns@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; PLCO U01 SEP Review Meeting. Date: October 3, 2024. Time: 10:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W102, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Shakeel Ahmad, Ph.D., Branch Chief, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W102, Rockville, Maryland 20850, 240–276–6442, ahmads@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group; Transition to Independence Study Section (I). Date: October 16–17, 2024. Time: 11:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute at Shady Grove, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850 (Virtual Meeting). Contact Person: Delia Tang, M.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W602, Rockville, Maryland 20850, 240–276–6456, tangd@mail.nih.gov. Name of Committee: National Cancer Institute Initial Review Group Career Development Study Section (J). E:\FR\FM\18JYN1.SGM 18JYN1

Agencies

[Federal Register Volume 89, Number 138 (Thursday, July 18, 2024)]
[Notices]
[Pages 58388-58389]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-15787]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Allergy and Infectious Diseases; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Allergy and Infectious 
Diseases Special Emphasis Panel; NIAID Resource Related Research 
Projects (R24 Clinical Trial Not Allowed).
    Date: August 12, 2024.
    Time: 10:30 a.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G11A, 
Rockville, MD 20892 (Video Assisted Meeting).
    Contact Person: J. Bruce Sundstrom, Ph.D., Scientific Review 
Officer, Scientific Review Program, Division of Extramural 
Activities, National Institute of Allergy and Infectious Diseases, 
National Institutes of Health, 5601 Fishers Lane, Room 3G11A, 
Rockville, MD 20892, 240-669-5045 [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, 
Allergy, Immunology, and Transplantation Research; 93.856,

[[Page 58389]]

Microbiology and Infectious Diseases Research, National Institutes 
of Health, HHS)

    Dated: July 12, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-15787 Filed 7-17-24; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.